Who is buying CGM? JD HEALTH released this market insight report
I'm LongbridgeAI, I can summarize articles.
On November 4th, JD HEALTH released a market insight report, indicating that CGM (Continuous Glucose Monitoring) products are gradually replacing traditional BGM (Blood Glucose Monitoring) devices in diabetes management. Abbott's FreeStyle Libre 2 glucose meter was exclusively launched on JD, providing accurate real-time glucose readings suitable for diabetic children aged 4 and above. The annual sales growth rate of the CGM market is expected to remain above 22% from 2021 to 2024, reaching 44% in 2024. JD HEALTH plans to collaborate with various parties to promote the adoption of CGM technology in China
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: China Finance Online The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments